Factsheet - MorphoSys

Product Pipeline
Program, Partner Indication Discovery Pre-clinic Phase 1 Phase 2 Phase 3 Market
MOR10 3, GSK Rheumatoid Arthritis
MOR208 B-cell Malignancies
MOR10 3, GSK Multiple Sclerosis
MOR202, Celgene/MOR Multiple Myeloma
Gantenerumab, Roche Alzheimer’s Disease
Guselkumab, Janssen/J&J Psoriasis
Guselkumab, Janssen/J&J Rheumatoid Arthritis
BHQ880, Novartis Cancer
BYM338, Novartis Musculoskeletal
NOV-3, Novartis n. d.
LGF316, Novartis Ophthalmology
OMP-59R5, OncoMed Cancer
BAY94-9343, Bayer HealthCare Cancer
BI-1, Boehringer Ingelheim n. d.
CNTO 3157, Janssen/J&J Asthma
CNTO-5, Janssen/J&J Inflammation
VAY736, Novartis Inflammation
LJM716, Novartis Cancer
Vantictumab, OncoMed Cancer
PFE-1, Pfizer Cancer
NOV-7, Novartis Ophthalmology
1. Partnered Products
MorphoSys’s partnered product pipeline comprises more than
70 antibody programs covering a range of indications. The pipeline
spans a number of successful partnerships which have been
established over the last 12 years since the HuCAL technology
was introduced. Of the programs in development, 17 are pre -
sently in human clinical trials and around 20 in preclinical
evaluation.
2. Proprietary Products
MorphoSys develops proprietary therapeutic antibody candidates
in the areas of inflammation and oncology. By conducting
the discovery, pre-clinical and early clinical development itself,
MorphoSys is building a valuable portfolio of proprietary drugs.
Currently, the proprietary product portfolio comprises the following
clinical stage programs, two of which MorphoSys could
partner successfully in 2013:
MOR103 (GlaxoSmithKline)
In June 2013 MorphoSys signed a global agreement with GlaxoSmithKline
(GSK) to develop and commercialize MOR103.
MOR103 is a HuCAL antibody directed against GM-CSF, a thera -
peutic target for the treatment of inflammatory diseases that
has great potential in a number of indications where current
treat ments are inadequate. A clinical phase 1b/2a study in
patients with RA has been completed and reported excellent
data on safety and efficacy in September 2012. In addition to
CONTACT
MorphoSys AG
Lena-Christ-Str. 48
82152 Martinsried/Planegg
Germany
Phone: +49 (0) 89 899 27-0
Fax: +49 (0) 89 899 27-222
Email: info@morphosys.com
Website: www.morphosys.com
the RA trial, MOR103 is currently being tested in a phase 1b trial
in patients with multiple sclerosis.
MOR202 (Celgene)
In July 2013 MorphoSys and Celgene signed an agreement to
jointly develop MOR202 globally and to co-promote MOR202 in
Europe. MOR202 is a HuCAL antibody directed against CD38, a
promising therapeutic target for the treatment of multiple myeloma
and certain leukemias. MOR202 is currently being tested
in a phase 1/2a trial in multiple myeloma patients.
MOR208
MOR208 is a humanized monoclonal antibody in-licensed from
Xencor, which targets the antigen CD19. The antibody incor -
porates an optimized Fc portion, which further enhances its ability
to kill malignant CD-19-bearing B-cells. MOR208 is being
developed for the treatment of B-cell malignancies and autoimmune
diseases. The program has concluded a phase 1 trial in
patients with CLL and is now being evaluated in two phase 2
studies in ALL and NHL.
Management
Management Board
Dr. Simon E. Moroney, Chief Executive Officer
Jens Holstein, Chief Financial Officer
Dr. Arndt Schottelius, Chief Development Officer
Dr. Marlies Sproll, Chief Scientific Officer
HuCAL ® , HuCAL GOLD ® , HuCAL PLATINUM ® , CysDisplay ® , RapMAT ® , arYla ® , Ylanthia ® and 100 billion high potentials ® are registered trademarks of MorphoSys AG.
Slonomics ® 2013 July
is a registered trademark of Sloning BioTechnology GmbH, a subsidiary of MorphoSys AG. Version::